NTP42 Demonstrates Key Cardioprotective Benefits in Newly-published Preclinical Findings
ATXA Therapeutics have today published a new paper detailing results of its lead drug candidate NTP42 in preclinical models of pulmonary...
NTP42 Demonstrates Key Cardioprotective Benefits in Newly-published Preclinical Findings
ATXA Therapeutics receives Funding through the European Innovation Council Accelerator Programme
ATXA Presentation at ERS International Congress 2022
European Commission publish article on ATXA's PAH-HOPE project
ATXA Presentation at ESC Congress 2021
Newly-published preclinical findings for ATXA Therapeutics' NTP42
World Orphan Drug Virtual Conference
Jonathan Langley Appointment
ATXA Therapeutics looks to raise $30m to secure regulatory approval
Publication of preclinical findings for ATXA Therapeutics' NTP42
100 Hot Start Ups.